OKYO Pharma Limited

NASDAQ:OKYO

Biotechnology

Healthcare
$1.10 +0.64%

+$0.01 today

Market cap
$57.73M
Beta
0.02
P/E (TTM)
-12.8
EPS (TTM)
-$0.12
52W Low $1.42High $3.35

Volume 0.24M

Average 0.07M

OKYO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

OKYO Pharma LimitedNASDAQ: OKYO

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Sep 2025

Weighted avg shares (diluted) grows 11.5% year over year

Q2 FY2026 weighted avg shares (diluted) of 37.42M shares rose 11.5% year over year. Over 3 fiscal years it compounded at +37.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2025
37.42M— QoQ
Last fiscal yearMar 2025
39.49M+34.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.5%——
1 year+34.6%——
3-year CAGR+37.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
39.49M USD
Year-over-year change
+34.6%
4-year CAGR
+39.8%

Weighted Avg Shares (Diluted) vs competitors

How OKYO compares with its peers on the latest reported figures

  • OKYO's FY2025 weighted avg shares (diluted) of 39.49M shares is the 6th highest of the 10 companies compared; the peer median is 59.14M shares.
  • Its year-over-year change of +34.6% is the 3rd highest of 10, against a peer median of +5.9%.
  • Over three fiscal years its annual growth of +37.9% compares with a peer median of +13.5%.
OKYO Competitors Peer median
Weighted Avg Shares (Diluted) for OKYO and competitors
Company Period LTM YoY 3-year CAGR
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
WHWKWhitehawk Therapeutics IncLTM Mar 202669.18M +155.7%+40.1%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
PLRXPliant Therapeutics, Inc.LTM Mar 202661.49M +1.3%+13.5%
TLSATiziana Life Sciences LtdFY202559.14M +10.9%+5.2%
OKYOOKYO Pharma LimitedFY202539.49M +34.6%+37.9%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
COYACoya Therapeutics, Inc.LTM Mar 202616.73M +5.9%+18.9%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
SLGLSol-Gel Technologies Ltd.LTM Mar 20262.8M -90.0%-50.6%
Peer median (excluding OKYO) 59.14M+5.9%+13.5%

Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Revenue00000
Cost of Revenue13.09K2.42K3.8K3.87K2.56K
Gross Profit(13.09K)(2.42K)(3.8K)(3.87K)(2.56K)
Gross Margin—————
Research & Development348.35K1.61M6.34M8.24M2.25M
Selling, General & Admin2.97M4.93M6.75M7.45M4.93M
Operating Expenses3.37M6.22M6.34M15.69M7.19M
Depreciation & Amortization13.11K2.33K3.8K3.87K2.56K
EBITDA(3.35M)(6.22M)(13.18M)(15.75M)(7.08M)
EBITDA Margin—————
Operating Income(4.13M)(6.23M)(13.09M)(15.69M)(7.19M)
Operating Margin—————
Interest Income00005.47K
Interest Expense1.12K096.69K1.05M883.65K
Other Income / Expenses754.85K13.58K(196.62K)(1.11M)(781.2K)
Income Before Tax(3.38M)(6.22M)(13.28M)(16.8M)(7.97M)
Pre-Tax Margin—————
Income Tax Expense(24.99K)(787K)(12.2K)22.42K(3.26M)
Net Income(3.35M)(5.43M)(13.27M)(16.83M)(4.71M)
Net Margin—————
EPS (Basic)(0.32)(0.36)(0.60)(0.00)(0.12)
EPS (Diluted)(0.32)(0.36)(0.60)(0.00)(0.12)
Weighted Avg Shares10.35M15.06M22.26M29.34M39.49M
Weighted Avg Shares (Diluted)10.35M15.06M22.26M29.34M39.49M

OKYO Pharma Limited

NASDAQ:OKYO

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.